Quantitative Concept – Page 25

AstraZeneca and Daiichi Sankyo’s Dato-DXd Fails to Meet Overall Survival Goal in NSCLC Study, FDA Decision Looms

8 months ago talkbio0Tagged AstraZeneca, Clinical Research, Daiichi, Dato-DXd, Datopotamab deruxtecan, Decision, Non-Small Cell Lung Carcinoma, Overall Survival, Sankyo, TROPION-Lung01, United States Food and Drug Administration

AstraZeneca, Daiichi Sankyo, Dato-DXd (datopotamab deruxtecan), Non-small cell lung cancer (NSCLC), Overall survival (OS), FDA decision, TROPION-Lung01 study

Superluminal Medicines Secures $120M Series A Funding to Advance Membrane Receptor Drugs into Clinical Trials

8 months ago talkbio0Tagged AI-focused, Clinical Trials, Eli, Eli Lilly, Funding, Investments, Membrane receptor, Series, Superluminal Medicines

Superluminal Medicines, Series A funding, membrane receptor drugs, clinical trials, AI-focused biotech, Eli Lilly investment

WCLC24: Rybrevant-Lazcluze Combination Shows Enhanced Survival Benefit Over Tagrisso in EGFR-Mutated NSCLC

8 months ago talkbio0Tagged Benefit, Continuance of life, EGFR-mutated, first-line, Lazcluze, MARIPOSA, Non-Small Cell Lung Carcinoma, Rybrevant, Tagrisso, WCLC24

Rybrevant, Lazcluze, Tagrisso, EGFR-mutated NSCLC, MARIPOSA study, WCLC24, survival benefit, first-line treatment.

Promising Phase 2 Results for Ifinatamab Deruxtecan in Small Cell Lung Cancer

8 months ago talkbio0Tagged Cell Lung Cancer, Daiichi, Deruxtecan, ifinatamab, Phase 2 trial, Sankyo, Small, Technology, therapeutic autologous dendritic cells

Ifinatamab Deruxtecan, Small Cell Lung Cancer, Phase 2 Trial, ADC Technology, Daiichi Sankyo, Merck

Superluminal Secures $120M Series A Funding to Advance Membrane Receptor Drugs into Clinical Trials

8 months ago talkbio0Tagged Clinical Trials, Eli, Eli Lilly, Funding, Membrane receptor, Series, Superluminal

Superluminal, Eli Lilly, Series A funding, membrane receptor drugs, clinical trials, biotech, pharmaceuticals